Certain information in this exhibit has been omitted because it is permitted to be omitted by applicable regulatory guidance.Separation Agreement • May 8th, 2023 • Coherus BioSciences, Inc. • Biological products, (no disgnostic substances) • California
Your resignation from the position of Chief Scientific Officer will be effective March 31, 2023 (the “Separation Date”). This letter (the “Agreement”) provides information regarding the mutual separation package agreement offered to you by Coherus Biosciences, Inc. (the “Company”) should you agree to sign this Agreement.
SECOND AMENDMENT AND WAIVERSecond Amendment and Waiver • May 8th, 2023 • Coherus BioSciences, Inc. • Biological products, (no disgnostic substances)
This SECOND AMENDMENT AND WAIVER (this “Amendment and Waiver”), dated and effective as of February 6, 2023 (the “Second Amendment Effective Date”), is made by and among COHERUS BIOSCIENCES, INC., a Delaware corporation (as “Borrower” and a Credit Party), BIOPHARMA CREDIT PLC, a public limited company incorporated under the laws of England and Wales with company number 10443190 (as the “Collateral Agent”), BPCR LIMITED PARTNERSHIP, a limited partnership established under the laws of England and Wales with registration number LP020944 (as a “Lender”) and BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP, a Cayman Islands exempted limited partnership acting by its general partner, BioPharma Credit Investments V GP LLC (as a “Lender”).
